NCT01522976 2026-03-18
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
59 trialsNCT05283720 2026-03-03
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Phase 2 Recruiting
NCT01446133 2026-01-27
Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01496976 2025-12-19
Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02005289 2025-12-15
Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT06517017 2025-11-28
UltraFrailMM
University of Utah
Phase 2 Recruiting
NCT01351896 2025-11-20
Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01729091 2025-05-09
Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00848328 2025-04-24
Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma
University of California, Davis
Phase 2 Terminated
NCT01199575 2024-08-15
Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
University of California, San Diego
Phase 2 Completed
NCT01754857 2023-06-27
Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL
University of Wisconsin, Madison
Phase 2 Completed
NCT00783367 2023-03-30
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT02225275 2022-09-28
Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01241786 2022-07-20
VZCLLPI0146
Hackensack Meridian Health
Phase 2 Terminated
NCT00352365 2022-02-11
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT01125176 2022-01-21
ThRiL
Weill Medical College of Cornell University
Phase 2 Completed
NCT00792077 2021-07-01
A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01497496 2021-04-27
Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02309515 2021-01-19
Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis
Mayo Clinic
Phase 2 Terminated
NCT02472691 2020-05-28
AZALENA
Heinrich-Heine University, Duesseldorf
Phase 2 Completed
NCT00632359 2020-02-10
Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00899431 2020-01-27
Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02538965 2020-01-07
A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Celgene
Phase 2 Completed
NCT00974233 2019-12-02
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
University of Wisconsin, Madison
Phase 2 Completed
NCT01743859 2019-10-08
Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia
University of Colorado, Denver
Phase 2 Completed
NCT01358734 2019-06-25
A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia
Celgene
Phase 2 Completed
NCT01002755 2019-05-07
Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00860457 2018-11-21
Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)
Georgetown University
Phase 2 Completed
NCT00963105 2018-10-31
Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Celgene
Phase 2 Completed
NCT00535873 2018-08-21
Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01724177 2018-05-29
A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma
Celgene
Phase 2 Completed
NCT02371590 2018-02-23
Lenalidomide and Obinutuzumab for Previously Untreated CLL
University of California, San Diego
Phase 2 Withdrawn
NCT01442714 2018-01-03
Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS
Stanford University
Phase 2 Terminated
NCT01116193 2017-09-14
RV-405 LAL
Institut de Cancérologie de la Loire
Phase 2 Completed
NCT01419795 2017-07-27
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT00096044 2017-07-11
Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Roswell Park Cancer Institute
Phase 2 Completed
NCT00744536 2017-06-09
REMMYDYS
Sunnybrook Health Sciences Centre
Phase 2 Completed
NCT01011894 2017-05-18
Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02371577 2017-04-28
Revlimid
University of California, San Diego
Phase 2 Withdrawn
NCT01600053 2016-12-15
Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia
University of California, San Diego
Phase 2 Terminated
NCT01401322 2016-11-28
Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Stanford University
Phase 2 Terminated
NCT01459211 2016-11-08
LenD
University College, London
Phase 2 Completed
NCT00784927 2016-10-07
Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma
Mayo Clinic
Phase 2 Completed
NCT00751296 2016-06-16
Rev-CLL
University Health Network, Toronto
Phase 2 Terminated
NCT01274533 2016-05-23
Lenalidomide in HTLV-1 Adult T-Cell Leukemia
Columbia University
Phase 2 Completed
NCT01301820 2016-03-16
Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR)
French Innovative Leukemia Organisation
Phase 2 Completed
NCT00759603 2015-08-27
Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01271283 2015-06-04
Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00885508 2015-04-24
GFM-Chimio-Rev
Groupe Francophone des Myelodysplasies
Phase 2 Unknown
NCT00833534 2015-03-06
Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 2 Withdrawn